Key Points Non-GAAP earnings per share (EPS) of $2.25 in Q2 2025 far surpassed the analyst estimate of $0.32 and rose 923% year-over-year compared to Q2 2024 (non-GAAP adjusted diluted EPS per ADS).

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Purespring Therapeutics has received approval for its UK clinical trial application (CTA) for a Phase I/II trial of its lead ...

Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by ...

The regulator is allowing the firm to submit data on 4D-150 from a single Phase III trial and draw on readouts from previously conducted studies in wet AMD.

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

The European drug authority recommends refusal of marketing authorization after study shows no benefit over placebo.

The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the ...

Sarepta Therapeutics failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as ...

The EMA grants orphan designation status to medicines intended for the treatment, prevention or diagnosis of life-threatening or chronically debilitating diseases affecting fewer than 5 in 10,000 ...